Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose, Multiple Ascending Dose and Proof-of-Principle Study to Assess Safety, Tolerability, Pharmacodynamics, Immunogenicity, Exploratory Clinical Efficacy, and Pharmacokinetics of Intravenous Infusions of E2814 in Healthy Subjects and Subjects With Prodromal Alzheimer's Disease to Moderate Alzheimer's Dementia With and Without Detectable Tau Pathology

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose, Multiple Ascending Dose and Proof-of-Principle Study to Assess Safety, Tolerability, Pharmacodynamics, Immunogenicity, Exploratory Clinical Efficacy, and Pharmacokinetics of Intravenous Infusions of E2814 in Healthy Subjects and Subjects With Prodromal Alzheimer's Disease to Moderate Alzheimer's Dementia With and Without Detectable Tau Pathology

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs E 2814 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Eisai Inc
  • Most Recent Events

    • 22 Feb 2019 Status changed from planning to not yet recruiting.
    • 07 Dec 2018 According to an Eisai Co Ltd media release, this trial is expected to be initiated in early 2019.
    • 06 Dec 2018 According to an Eisai Co Ltd media release, the company and University College London (UCL) have commenced preparations for this study. The study expects to commence within fiscal 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top